Abstract

Alzheimer’s disease (AD) is characterized by amyloid beta (Aβ) plaques in the brain detectable by highly invasive in vivo brain imaging or in post-mortem tissues. A non-invasive and inexpensive screening method is needed for early diagnosis of asymptomatic AD patients. The shared developmental origin and similarities with the brain make the retina a suitable surrogate tissue to assess Aβ load in AD. Using curcumin, a FluoroProbe that binds to Aβ, we labeled and measured the retinal fluorescence in vivo and compared with the immunohistochemical measurements of the brain and retinal Aβ load in the APP/PS1 mouse model. In vivo retinal images were acquired every 2 months using custom fluorescence scanning laser ophthalmoscopy (fSLO) after tail vein injections of curcumin in individual mice followed longitudinally from ages 5 to 19 months. At the same time points, 1–2 mice from the same cohort were sacrificed and immunohistochemistry was performed on their brain and retinal tissues. Results demonstrated cortical and retinal Aβ immunoreactivity were significantly greater in Tg than WT groups. Age-related increase in retinal Aβ immunoreactivity was greater in Tg than WT groups. Retinal Aβ immunoreactivity was present in the inner retinal layers and consisted of small speck-like extracellular deposits and intracellular labeling in the cytoplasm of a subset of retinal ganglion cells. In vivo retinal fluorescence with curcumin injection was significantly greater in older mice (11–19 months) than younger mice (5–9 months) in both Tg and WT groups. In vivo retinal fluorescence with curcumin injection was significantly greater in Tg than WT in older mice (ages 11–19 months). Finally, and most importantly, the correlation between in vivo retinal fluorescence with curcumin injection and Aβ immunoreactivity in the cortex was stronger in Tg compared to WT groups. Our data reveal that retina and brain of APP/PS1 Tg mice increasingly express Aβ with age. In vivo retinal fluorescence with curcumin correlated strongly with cortical Aβ immunohistochemistry in Tg mice. These findings suggest that using in vivo fSLO imaging of AD-susceptible retina may be a useful, non-invasive method of detecting Aβ in the retina as a surrogate indicator of Aβ load in the brain.

Highlights

  • Alzheimer’s disease (AD) is a chronic irreversible neurodegenerative disease that leads to progressive memory loss and cognitive impairment

  • These data indicated that the Aβ immunoreactivity reliably detects the age-related increase in cortical Aβ load in the amyloid beta peptides (APP)/PS1 mouse brain (Hsiao et al, 1996; Radde et al, 2006)

  • The amyloid cascade hypothesis states that Aβ accumulation, via post-translational proteolytic cleavage of amyloid beta peptides (APP), precedes aggregation into senile plaques and subsequent neuronal damage (Beyreuther and Masters, 1991; Hardy and Allsop, 1991; Selkoe, 1991; Hardy and Higgins, 1992)

Read more

Summary

Introduction

Alzheimer’s disease (AD) is a chronic irreversible neurodegenerative disease that leads to progressive memory loss and cognitive impairment. While no cure presently exists, early diagnosis of AD can lead to treatment that helps to manage the symptoms, maximize functionality, and maintain quality of life (Sevigny et al, 2016). The major challenge for early AD diagnosis is the identification of biomarkers by non-invasive methods that could be readily deployable to the at-risk population. This goal is further challenged because the exact pathophysiology and corresponding onset of the disease remain poorly understood

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call